- Open Access
Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein
© The Author(s). 2017
- Received: 24 September 2016
- Accepted: 25 January 2017
- Published: 1 February 2017
The macrophage, one of the several key immune cell types, is believed to be involved in tumorigenesis. However, the mechanism of macrophages promoting tumor progression is largely unknown.
The differentially secreted proteins of M1 and M2 macrophages were analyzed by mass spectrometry. We performed GST pull-down assay for the identification of cell-membrane receptors that interact with chitinase 3-like protein 1 (CHI3L1) protein. The mouse model was used to validate the function of CHI3L1 in cancer metastasis in vivo. Protein phosphorylation and gene expression were performed to study the signaling pathway activation of cancer cells after CHI3L1 treatment.
M2 macrophage-secreted CHI3L1 promoted the metastasis of gastric and breast cancer cells in vitro and in vivo. The CHI3L1 protein functioned by interacting with interleukin-13 receptor α2 chain (IL-13Rα2) molecules on the plasma membranes of cancer cells. Activation of IL-13Rα2 by CHI3L1 triggered the activation of the mitogen-activated protein kinase signaling pathway, leading to the upregulated expression of matrix metalloproteinase genes, which promoted tumor metastasis. The results of this study indicated that the level of CHI3L1 protein in the sera of patients with gastric or breast cancer was significantly elevated compared with those of healthy donors.
Our study revealed a novel aspect of macrophages with respect to cancer metastasis and showed that CHI3L1 could be a marker of metastatic gastric and breast cancer in patients.
- Cancer metastasis
- M2 macrophage
Cell migration is an essential process for the development and maintenance of multicellular organisms and is defined as the orchestrated movement of cells in a particular direction to a specific location . To migrate, a cell must modify its shape to be able to interact with the surrounding tissue structures. Therefore, the extracellular matrix (ECM) serves as a substrate as well as a barrier for an advancing cell body . Cell migration is an integrated, multistep process that contributes to tissue repair and regeneration, orchestrates embryonic morphogenesis and drives disease progression. During cell migration, the moving cell first becomes polarized and elongated. A pseudopod is then formed, which attaches to the ECM substrate. Subsequently, regions of the leading edge contract, thereby generating a traction force that leads to the gradual forward gliding of the cell body and its trailing edge. Metastasis, which involves the migration of cancer cells from the primary tumor to a distant organ or tissue, is the most frequent cause of death for patients with cancer. Cancer cells utilize cell migration mechanisms that are similar to those exhibited by non-neoplastic cells during physiological processes . The steps of metastasis include tumor cell adhesion to and invasion of basement membranes and the surrounding tissue, intravasation into blood vessels, survival in the bloodstream, extravasation, and growth at different organ sites . Only a small proportion of tumor cells invade and disseminate. However, the molecular mechanisms underlying metastasis are still poorly understood because of their apparent complexity.
Tumor progression is controlled by crosstalk between cancer cells and other cell types within the tumor microenvironment. The tumor microenvironment includes proliferating tumor cells, blood vessels, the tumor stroma, inflammatory cells, and a variety of associated tissue-type cells. This unique environment forms over the course of tumor progression due to the interactions of tumor cells with the host. This microenvironment is shaped and dominated by the tumor, which orchestrates molecular and cellular events occurring in the surrounding tissues. Although various immune effector cells are recruited to the tumor site, their anti-tumor functions are downregulated, largely in response to tumor-derived signals. Immune effector cells in the tumor microenvironment not only fail to perform anti-tumor functions but are co-opted to promote tumor growth . Macrophages are a key component of the tumor microenvironment that act as facilitators of tumor cell migration and invasion, matrix degradation, and angiogenesis. The density of macrophages in the tumor microenvironment has been found to be a prognostic marker of poor outcome for a variety of carcinomas. Evidence from clinical and experimental studies has indicated that tumor-associated macrophages (TAMs) promote solid-tumor metastasis by releasing a variety of cytokines, including chemokines, inflammatory factors, and growth factors [4–6]. For example, macrophages can promote angiogenesis by secreting IL-1, VEGF, and MMP-2 . Growth factors and proteases produced by macrophages can initiate tumorigenesis and enhance tumor progression . However, many cytokines that are produced by cancer cells themselves also contribute to carcinogenesis . Elevated cytokine expression may be a diagnostic cancer marker. Currently, TAM cytokine profiles are largely unknown. It is unclear whether there are some exclusively TAM-derived cytokines that are functionally essential to tumor progression.
There are different types of macrophages, such as M1 and M2 macrophages . Phagocytosis mediated by macrophages (M1 macrophages) is essential to the immune response of animals, as revealed in our previous studies [11–14]. M2 macrophages can suppress inflammatory responses as well as promote angiogenesis and tissue remodeling and repair . Our previous studies indicated that inhibition of microRNA-100 triggered apoptosis of breast and cancer cells by inhibiting ubiquitination-mediated p53 degradation [15, 16], revealing a vital role of microRNAs in tumor progression. To further explore the role of macrophages in tumor progression, the proteins secreted by macrophages were characterized in this study. The results indicated that M2 macrophages are recruited by tumor cells. The M2-secreted chitinase 3-like protein 1 (CHI3L1) promoted the metastasis of gastric and breast cancer cells by triggering the mitogen-activated protein kinase (MAPK) signaling pathway. Therefore, our study revealed a novel macrophage-mediated mechanism that underlies cancer cell metastasis.
Identification of CHI3L1 secreted by M2 macrophages
M1 and M2 macrophages were cultured in serum-free medium for 24 h. Then, the culture supernatants were collected and were dialysed against 1 L of distilled water overnight at 4 °C. The secreted proteins were resolved on a 15% SDS-PAGE denaturing gel and were visualized using Coomassie Brilliant Blue. The protein band of interest was removed for mass spectrometry analysis.
Identification of cell-membrane receptors that interact with CHI3L1 protein
GST (glutathione S transferase)-conjugated CHI3L1 protein was expressed in E. coli BL21 cells and was purified using standard protocols. Glutathione-Sepharose beads (GE Healthcare, Waukesha, WI, USA) coupled with either GST or with the GST-CHI3L1 purified protein were incubated with the solubilized membrane proteins for 1 h at 4 °C. The membrane proteins of the gastric and breast cancer cells were extracted using a ProteoExtract Native Membrane Protein Extraction kit (Calbiochem, San Diego, CA, USA) according to the manufacturer’s instructions. After rinsing the beads three times with washing buffer (50 mM HEPES-KOH, 150 mM NaCl, 1 mM MgCl2, 0.2% Triton-X-100, pH 7.2), the proteins bound to the beads were separated using 10% SDS-PAGE and were visualized using Coomassie Brilliant Blue R-250 staining. The differentially apparent proteins were excised from the gel and were identified using mass spectrometry.
Assessment of breast cancer metastasis in vivo
The breast cancer metastasis assay was conducted in mice. All the experiments using animals were performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee (IACUC). Female nude mice of between 5 and 6 weeks old were used in this study. Breast cancer cells (i.e., 2 × 105 MDA-MB-231 cells or 8 × 105 MDA-MB-435 cells) stably expressing the firefly luciferase reporter were mixed with 100 μl of PBS, and the mixture was intravenously injected into the mice. 3 days later, either recombinant CHI3L1 protein (rCHI3L1) or PBS (as the control) was injected into the mice via the tail vain at a dosage of 100 μg/kg of body weight. rCHI3L1 or PBS was injected twice a week over a 7-week (MDA-MB-231) or 11-week period (MDA-MB-435). For in vivo imaging, the mice were given the substrate D-luciferin by intraperitoneal injection at a dosage of 150 mg/kg in PBS, after which lung metastasis was quantified every 2 weeks by bioluminescence imaging using an IVIS Spectrum Imaging System (Perkin Elmer). Bioluminescence analysis was performed using Living Image software version 4.5 (Perkin Elmer). The solid tumors of mouse lungs were harvested at the end of the experimental period for further evaluation.
Detection of CHI3L1 protein in the sera of healthy donors and metastatic cancer patients
Serum samples were obtained from patients in The First Affiliated Hospital of Bengbu Medical College, China. The samples were collected with the informed consent of the patients, and all related procedures were performed with the approval of the internal review and ethics boards of the indicated hospital. For the co-immunoprecipitation assay, the sera were centrifuged at 12,000 × g and 4 °C for 10 min. Then, the supernatants were diluted in EBC lysis buffer (50 mM Tris–HCl, 120 mM NaCl, and 2 mM PMSF). To remove the antibodies from the sera, the supernatants were incubated with Dynabeads® protein G (Invitrogen) with gentle rotation at 4 °C for 2 h. After centrifugation at 5,000 × g for 5 min, the supernatants were incubated with the anti-CHI3L1 IgG-conjugated Dynabeads® protein G with gentle rotation at 4 °C overnight. Subsequently, the mixture was washed twice using EBC lysis buffer and was analyzed by western blotting using the anti-CHI3L1 IgG.
All biological experiments were repeated three times independently. Numerical data were analyzed using a one-way analysis of variance. The statistical significance between treatments was analyzed using Student’s t test.
Tumor recruits M2 macrophages
Peripheral blood monocytes-derived M2 macrophages promote cancer cell metastasis
To further explore the effects of macrophages derived from human samples on cancer cell metastasis, the peripheral blood monocytes of healthy humans were induced to differentiate into M1 and M2 macrophages using LPS and IL-4, respectively. Then, the cancer cells were co-cultured with isolated M1 or M2 macrophages. The results indicated that co-culturing isolated M2 macrophages and gastric cancer cells (MKN-45 and AGS) or breast cancer cells (MDA-MB-231, MDA-MB-435, and MDA-MB-468) led to a significant increase in the number of migrated cancer cells compared with the control (i.e., medium alone) (Fig. 2g). However, M1 cells had no effect on cancer cell migration (Fig. 2g). The data showed that the monocyte-derived M2 macrophages promoted the migration of gastric cancer cells and breast cancer cells.
To assess the effects of isolated M2 macrophages on cancer cell adhesion and invasion, M1 or M2 macrophages were co-cultured with the cancer cells, and the co-cultures were subjected to adhesion and invasion assays. MKN-45 or AGS gastric cancer cell adhesion was significantly enhanced by co-culturing with M2 but not M1 cells (Fig. 2h). The results obtained using MDA-MB-231, MDA-MB-435, and MDA-MB-468 breast cancer cells were similar to those obtained using gastric cancer cells (Fig. 2h). The invasion assays showed that co-culturing isolated M2 macrophages and gastric or breast cancer cells resulted in a significant increase of cancer cell invasion, whereas isolated M1 cells had no effect on cancer cell invasion (Fig. 2i).
Taken together, the above findings indicate that monocyte-derived M2 macrophages promote the metastasis of gastric and breast cancer cells.
M2 macrophage-secreted CHI3L1 mediates cancer cell metastasis
Recombinant CHI3L1 (rCHI3L1) protein was added to gastric cancer cell culture (MKN-45 and AGS), breast cancer cell culture (MDA-MB-231, MDA-MB-435, and MDA-MB-468), or melanoma cell culture (A375) for cell migration assays using Boyden chambers. The results showed that the migration of gastric or breast cancer cells was significantly enhanced by the recombinant CHI3L1 protein in a dose-dependent manner, whereas CHI3L1 protein had no effect on the migration of A375 melanoma cells compared with the controls (Fig. 3c). To explore the role of CHI3L1 in cancer cell invasion and adhesion, gastric cancer cells (MKN-45 and AGS) or breast cancer cells (MDA-MB-231, MDA-MB-435, and MDA-MB-468) were cultured in media containing the recombinant CHI3L1 protein and were subsequently subjected to invasion and adhesion assays. The results showed that gastric and breast cancer cell adhesion to fibronectin was significantly increased by treatment with CHI3L1 protein (Fig. 3d), indicating that CHI3L1 played a positive role in cancer cell adhesion. Moreover, CHI3L1 protein was shown to significantly enhance the invasiveness of MKN-45, AGS, MDA-MB-231, MDA-MB-435, and MDA-MB-468 cells compared with the controls (Fig. 3e).
To confirm the effects of M2 cells-secreted CHI3L1 protein on cancer cell metastasis (cell migration, adhesion and invasion), a polyclonal anti-CHI3L1 antibody was added to the co-cultures of cancer cells and healthy human peripheral blood monocytes-derived M2 macrophages to neutralize the activity of CHI3L1. The findings revealed that the addition of anti-CHI3L1 led to a significant decrease of gastric and breast cancer cell migration in the presence of isolated M2 macrophages compared with the controls (Fig. 3f), indicating that CHI3L1 played a key role in cancer cell migration. To neutralize the effect of CHI3L1 on gastric and breast cancer cell adhesion, anti-CHI3L1 was added to the cell cultures. In the presence of isolated M2 macrophages, the number of adherent cancer cells was significantly reduced by the antibody compared with the controls (Fig. 3g), showing that CHI3L1 appeared to be required for cancer cell adhesion. When the antibody directed against CHI3L1 (anti-CH3L1) was present in co-cultures of isolated M2 cells and gastric or breast cancer cells, the number of invaded cancer cells was significantly decreased compared with that of untreated co-cultures of isolated M2 cells and cancer cells (Fig. 3h). These findings revealed that monocyte-derived M2 macrophages promoted the metastasis of gastric and breast cancer cells via the CHI3L1 protein.
To explore the effects of silencing CHI3L1 gene expression on cancer cell metastasis, the expression level of the CHI3L1 gene was knocked down using CHI3L1-siRNA in isolated M2 macrophages compared with the control level (Fig. 3i). The results showed that silencing CHI3L1 expression in isolated M2 cells led to significant decreases of cancer cell migration, adhesion, and invasion compared with the control levels (Fig. 3j–l). These findings indicated that CHI3L1 was required for gastric and breast cancer cell metastasis.
To determine the distribution of CHI3L1 protein in cancer tissues, an immunohistochemistry analysis using anti-CHI3L1 and an immunofluorescent double staining using anti-CHI3L1 and anti-CD206 were conducted. The results showed that CHI3L1 protein was localized in the stroma of gastric carcinomas (Fig. 3m). However, no positive signal was observed in the pericarcinous tissue (Fig. 3m). These findings suggested that CHI3L1 protein plays an important role in cancer progression.
Collectively, the data described above indicated that M2 macrophages promote gastric and breast cancer cell metastasis (cell migration, adhesion, and invasion) via the M2 macrophage-secreted CHI3L1 protein.
The mechanism underlying CHI3L1-activated gastric and breast cancer cell metastasis
Previous studies have revealed that the activation of IL-13Rα2 by IL-13 triggers the MAPK signaling pathway by phosphorylating extracellular signal-regulated kinase (ERK) 1/2 and c-Jun N-terminal kinase (JNK) in pancreatic and ovarian cancers and the phosphoinositide 3-kinase (PI3K)/AKT pathway by phosphorylating Src and AKT in colorectal cancer [17–19]. As shown in Fig. 4d, adding CHI3L1 protein to gastric cancer cell (MKN-45 and AGS) and breast cancer cell (MDA-MB-231, MDA-MB-435, and MDA-MB-468) cultures promoted the phosphorylation of ERK and JNK but not Src and AKT, which was abolished by IL-13Rα2 gene silencing in cancer cells. These results indicated that the activation of IL-13Rα2 by CHI3L1 triggered only the MAPK signaling pathway in gastric and breast cancers.
In the MAPK signaling pathway, the phosphorylation of ERK 1/2 and JNK activates the AP (activator protein)-1 transcription factor family, including c-Fos and c-Jun, and thus promotes the expression of matrix metalloproteinases (MMPs) in cancer cells [19–21]. The luciferase reporter assays showed that AP-1 transcriptional activity in cancer cells was significantly increased by the addition of rCHI3L1 protein compared with the control (Fig. 4e), indicating that AP-1 transcriptional activity was activated by CHI3L1 protein. Western blots showed that the presence of CHI3L1 dramatically elevated the levels of c-Fos and c-Jun proteins in cancer cell nuclei (Fig. 4f), confirming the activation of the AP-1 family by CHI3L1. Further data indicated that the activation of the AP-1 family by CHI3L1 significantly upregulated the levels of MMP expression in cancer cells (Fig. 4g). However, different MMPs were upregulated by CHI3L1 in different cancer cell types. The results showed that knockdown of IL-13Rα2 gene expression in cancer cells significantly reduced the CHI3L1-induced activation of AP-1 transcription factors and upregulation of MMP gene expression in cancer cells (Fig. 4e–g).
To further explore the role of CHI3L1 protein in the CHI3L1-AP-1-MMP pathway, cancer cells were treated with ERK inhibitor (U0126) or JNK inhibitor (SP600125), followed by the addition of CHI3L1 protein in MKN-45 and MDA-MB-231 cells. The data presented that ERK inhibitor or/and JNK inhibitor resulted in decreased aggregation of c-Fos and c-Jun proteins in the nuclei of cancer cells compared with the control (Fig. 4h). At the same time, CHI3L1-induced upregulation of MMP genes in MKN-45 and MDA-MB-231 cancer cells was eliminated when treated with inhibitors (Fig. 4i).
Taken together, these findings demonstrated that the IL-13Rα2 receptor activated the MAPK signaling pathway following CHI3L1 stimulation, thus promoting cancer cell metastasis.
CHI3L1-mediated promotion of in vivo breast cancer lung metastasis
To evaluate whether in vivo cancer metastasis resulted from the activation of the MAPK signaling pathway by the CHI3L1-IL-13Rα2 interaction, the MAPK pathway in the metastatic tumors of mouse lungs was examined. All the mice treated with rCHI3L1 presented remarkably increased levels of phosphorylation of ERK and JNK but not Src and AKT compared with the controls (i.e., mice treated with PBS alone) (Fig. 5d); these results corresponded with those obtained using the cancer cell lines (Fig. 4f). Additionally, the c-Fos and c-Jun expression levels in the nuclei of metastatic tumors of mouse lungs were significantly upregulated in response to rCHI3L1 treatment (Fig. 5e); these results were also consistent with those obtained using the cancer cell lines (Fig. 4h). The MMP gene expression profiles in the metastatic tumors of all the mice treated with rCHI3L1 (Fig. 5f) were similar to those of the cancer cell lines (Fig. 4i). Based on the data obtained in our study, a diagram of the signaling cascades involved in CHI3L1-induced cancer cell metastasis was constructed and is shown in Fig. 5g.
Collectively, these data indicated that CHI3L1 protein promoted in vivo breast cancer metastasis by activating the IL-13Rα2 receptor and subsequently, the MAPK pathway.
High levels of CHI3L1 protein in the sera of patients with gastric or breast cancer
Based on examination of the Oncomine and the Gene Expression Omnibus (GEO) databases, high levels of CHI3L1 expression in human tissues correlated with the progression of both gastric cancer (Fig. 6b) and breast cancer (Fig. 6c). These collective data suggested a significant correlation between increased CHI3L1 expression and primary human tumorigenic progression.
Metastasis represents a continuum that begins with cancer cell invasion through the basement membrane into the surrounding stroma, which is followed by extravasation into the circulatory system and the establishment of neoplastic cell colonies at distant sites . There is increasing evidence that macrophages play important roles in modulating the tumor metastatic capacity . Macrophages originate from blood monocytes and differentiate into distinct macrophage types, which are typically identified as M1 (classically activated) and M2 (alternatively activated) macrophages. M1 macrophages are efficient immune effector cells that kill invading microorganisms and tumor cells, present antigens and produce high levels of T-cell stimulatory cytokines. M2 macrophages, however, have poor antigen-presenting capabilities . These cells produce factors that suppress T-cell proliferation and activity and are generally better adapted to promoting angiogenesis and tissue remodeling and repair. Increasing amounts of data have shown that tumor-associated macrophages (TAMs) are polarized M2 macrophages . Genetic studies in mice have indicated that decreased numbers of macrophages in tumors are associated with notably reduced cancer metastasis rates . Although it is known that cytokines secreted by TAMs facilitate cancer cell migration, few TAM cytokines have been investigated. It has been reported that the levels of TAM-derived tumor growth factor-β1 (TGF-β1), epidermal growth factor (EGF), chemokine [C-C motif] ligand 18 (CCL18), interleukin (IL)-18, IL-1β, and IL-8 are correlated with tumor progression [6, 26–30]. Paracrine loops of colony-stimulating factor-1 (CSF-1)/EGF and granulocyte-macrophage colony-stimulating factor (GM-CSF)/CCL18 between carcinoma cells and macrophages have been shown to lead to increased carcinoma cell invasion . However, little is known about the role of the proteins secreted by TAMs in cancer metastasis. The results of this study demonstrated that CHI3L1, which is secreted by M2 macrophages, promoted cancer metastasis by activating the IL-13 receptors of cancer cells. Our study revealed the existence of not only a novel M2-secreted oncogenic protein (not a cytokine) but also a novel mechanism underlying cancer metastasis.
CHI3L1, a glycoprotein, is highly expressed in human tumors . The administration of CHI3L1 has been shown to promote endothelial cell migration and tube formation in vitro but fails to protect cervical cancer cells against apoptosis induced by γ-irradiation . However, the effect of M2 macrophage-derived CHI3L1 on cancer metastasis is not previously addressed. The findings of this study revealed that CHI3L1 specifically bound to the interleukin (IL)-13 receptor α2 chain (IL-13Rα2) of gastric and breast cancer cells, thus promoting cancer metastasis. These findings were consistent with previously reported data . As a binding partner of IL-13Rα2, transmembrane protein 219 (TMEM219) plays a critical role in IL-13Rα2-mediated pulmonary melanoma metastasis . CHI3L1 stimulation leads to TGF-β1 production during lung metastasis . In our study, the results showed that the activation of IL-13Rα2 triggered the downstream MAPK signaling pathway through the phosphorylation of ERK 1/2 and JNK. The phosphorylation of ERK1/2 and JNK led to the recruitment of activator protein (AP)-1 family members (transcription factors) in the nuclei [19, 21] and thus promoted AP-1 target gene expression . The AP-1 target genes are a family of MMPs [19, 36–38]. In the stroma of invasive carcinomas, tumor cells produce a variety of proteases, including various MMPs, to degrade the basement membrane and the surrounding extracellular matrix (ECM), which leads to fibronectin being exposed to the tumor cells . Therefore, CHI3L1 could promote the regional or distal metastasis of cancer. Our data indicated that the CHI3L1 levels in the sera of patients with cancer were significantly elevated compared with those of healthy donors, which suggests its potential as a diagnostic marker of gastric and breast cancers.
In summary, these data showed that the M2-secreted chitinase 3-like protein 1 (CHI3L1) could promote the metastasis of gastric and breast cancer cells by triggering the mitogen-activated protein kinase (MAPK) signaling pathway. In this context, CHI3L1 has the potential to be a therapeutic target for metastatic cancer. The clinical diagnostic strategy of assessing serum CHI3L1 protein levels merits future investigation.
This study was financially supported by the National Natural Science Foundation of China (31430089) and National Program on the Key Basic Research Project (2015CB755903).
Availability of data and materials
All data generated or analyzed during this study are included in this published article (and its Additional file 1).
XZ designed and supervised the study. YC and SZ performed the experiments. YC and SZ analyzed the data. YC and XZ wrote the paper. QW contributed to the research material. All authors approved the final version of the manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
Samples were collected with the informed consent of the donors, and all related procedures were performed with the approval of the internal review and ethics boards of The First Affiliated Hospital of Bengbu Medical College. All the experiments using animals were performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee (IACUC).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Legler DF, Uetz-von Allmen E, Hauser MA. CCR7: Roles in cancer cell dissemination, migration and metastasis formation. Int J Biochem Cell Bio. 2014;54:78–82.View ArticleGoogle Scholar
- Bravo-Cordero JJ, Hodgson L, Condeelis J. Directed cell invasion and migration during metastasis. Curr Opin Cell Bio. 2012;24:277–83.View ArticleGoogle Scholar
- Whiteside T. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904–12.View ArticlePubMedPubMed CentralGoogle Scholar
- Cho HJ, Jung JI, Lim DY, Kwon GT, Her S, et al. Bone marrow-derived, alternatively activated macrophages enhance solid tumor growth and lung metastasis of mammary carcinoma cells in a Balb/C mouse orthotopic model. Breast Cancer Res. 2012;14:R81.View ArticlePubMedPubMed CentralGoogle Scholar
- Kawata M, Koinuma D, Ogami T, Umezawa K, Iwata C, et al. TGF-β-induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by pro-inflammatory cytokines derived from RAW 264.7 macrophage cells. J Biochem. 2012;151:205–16.View ArticlePubMedGoogle Scholar
- Chen J, Yao Y, Gong C, Yu F, Su S, et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell. 2011;19:541–55.View ArticlePubMedPubMed CentralGoogle Scholar
- Fantin A, Vieira JM, Gestri G, Denti L, Schwarz Q, et al. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood. 2010;116:829–40.View ArticlePubMedPubMed CentralGoogle Scholar
- Balkwill F. TNF-α in promotion and progression of cancer. Cancer Metast Rev. 2006;25:409–16.View ArticleGoogle Scholar
- Lichtenberger BM, Tan PK, Niederleithner H, Ferrara N, Petzelbauer P, et al. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell. 2010;140:268–79.View ArticlePubMedGoogle Scholar
- Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122:787–95.View ArticlePubMedPubMed CentralGoogle Scholar
- Liu W, Han F, Zhang X. Ran GTPase regulates hemocytic phagocytosis of shrimp by interaction with myosin. J Proteome Res. 2009;8:1198–206.View ArticlePubMedGoogle Scholar
- Ye T, Tang W, Zhang X. Involvement of Rab6 in the regulation of phagocytosis against virus infection in invertebrates. J Proteome Res. 2012;11:4834–46.View ArticlePubMedGoogle Scholar
- Chen Y, Jiang C, Jin M, Gong Y, Zhang X. The role of Rab6 GTPase in the maturation of phagosome against Staphylococcus aureus. Int J Biochem Cell Bio. 2015;61:35–44.View ArticleGoogle Scholar
- Wu W, Zong R, Xu J, Zhang X. Antiviral phagocytosis is regulated by a novel Rab-dependent complex in shrimp Penaeus japonicus. J Proteome Res. 2008;7:424–31.View ArticlePubMedGoogle Scholar
- Gong Y, He T, Yang L, Yang G, Chen Y, et al. The role of miR-100 in regulating apoptosis of breast cancer cells. Sci Rep. 2015;5:11650.View ArticlePubMedPubMed CentralGoogle Scholar
- Yang G, Gong Y, Wang Q, Wang L, Zhang X. miR-100 antagonism triggers apoptosis by inhibiting ubiquitination-mediated p53 degradation. Oncogene. 2016;1–15 doi:10.1038/onc.2016.270
- Zhao Z, Wang L, Xu W. IL-13Rα2 mediates PNR-induced migration and metastasis in ERα-negative breast cancer. Oncogene. 2015;34:1596–607.View ArticlePubMedGoogle Scholar
- Barderas R, Bartolomé RA, Fernandez-Aceñero MJ, Torres S, Casal JI. High expression of IL-13 receptor α2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis. Cancer Res. 2012;72:2780–90.View ArticlePubMedGoogle Scholar
- Fujisawa T, Joshi B, Nakajima A, Puri RK. A novel role of interleukin-13 receptor α2 in pancreatic cancer invasion and metastasis. Cancer Res. 2009;69:8678–85.View ArticlePubMedGoogle Scholar
- Fujisawa T, Joshi BH, Puri RK. IL‐13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int J Cancer. 2012;131:344–56.View ArticlePubMedGoogle Scholar
- Kim JH, Kim JH, Kim SC, Yi Y-S, Yang WS, et al. Adenosine dialdehyde suppresses MMP-9-mediated invasion of cancer cells by blocking the Ras/Raf-1/ERK/AP-1 signaling pathway. Biochem Pharmacol. 2013;86:1285–300.View ArticlePubMedGoogle Scholar
- Tuveson DA, Neoptolemos JP. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell. 2012;148:21–3.View ArticlePubMedGoogle Scholar
- Chen Q, Zhang XH-F, Massagué J. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell. 2011;20:538–49.View ArticlePubMedPubMed CentralGoogle Scholar
- Qian B-Z, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39–51.View ArticlePubMedPubMed CentralGoogle Scholar
- Yeo E-J, Cassetta L, Qian B-Z, Lewkowich I, Li J-f, et al. Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer. Cancer Res. 2014;74:2962–73.View ArticlePubMedPubMed CentralGoogle Scholar
- Hou Z, Falcone DJ, Subbaramaiah K, Dannenberg AJ. Macrophages induce COX-2 expression in breast cancer cells: role of IL-1β autoamplification. Carcinogenesis. 2011;32:695–702.View ArticlePubMedPubMed CentralGoogle Scholar
- Massague J. TGFβ in cancer. Cell. 2008;134:215–30.View ArticlePubMedPubMed CentralGoogle Scholar
- Kaler P, Augenlicht L, Klampfer L. Macrophage-derived IL-1β stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3. Oncogene. 2009;28:3892–902.View ArticlePubMedPubMed CentralGoogle Scholar
- Yang J, Liao D, Chen C, Liu Y, Chuang TH, et al. Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem Cells. 2013;31:248–58.View ArticlePubMedGoogle Scholar
- Zhong L, Roybal J, Chaerkady R, Zhang W, Choi K, et al. Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment. Cancer Res. 2008;68:7237–45.View ArticlePubMedPubMed CentralGoogle Scholar
- Su S, Liu Q, Chen J, Chen J, Chen F, et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell. 2014;25:605–20.View ArticlePubMedGoogle Scholar
- Jeet V, Tevz G, Lehman M, Hollier B, Nelson C. Elevated YKL40 is associated with advanced prostate cancer (PCa) and positively regulates invasion and migration of PCa cells. Endocr Relat Cancer. 2014;21:723–37.View ArticlePubMedPubMed CentralGoogle Scholar
- Ngernyuang N, Francescone RA, Jearanaikoon P, Daduang J, Supoken A, et al. Chitinase 3 like 1 is associated with tumor angiogenesis in cervical cancer. Int J Biochem Cell Bio. 2014;51:45–52.View ArticleGoogle Scholar
- He CH, Lee CG, Dela Cruz CS, Lee CM, Zhou Y, et al. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor α2. Cell Rep. 2013;4:830–41.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee C-M, He CH, Nour AM, Zhou Y, Ma B, et al. IL-13Rα2 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses. Nat Commun. 2016;7:12752.View ArticlePubMedPubMed CentralGoogle Scholar
- Kook S-H, Jang Y-S, Lee J-C. Involvement of JNK-AP-1 and ERK-NF-κB signaling in tension-stimulated expression of type I collagen and MMP-1 in human periodontal ligament fibroblasts. J Appl Physiol. 2011;111:1575–83.View ArticlePubMedGoogle Scholar
- Lin C-M, Chen Y-H, Ma H-P, Wang B-W, Chiu J-H, et al. Silibinin inhibits the invasion of IL-6-stimulated colon cancer cells via selective JNK/AP-1/MMP-2 modulation in vitro. J Agr Food Chem. 2012;60:12451–7.View ArticleGoogle Scholar
- Nguyen P, Tsunematsu T, Yanagisawa S, Kudo Y, Miyauchi M, et al. The FGFR1 inhibitor PD173074 induces mesenchymal–epithelial transition through the transcription factor AP-1. Brit J Cancer. 2013;109:2248–58.View ArticlePubMedPubMed CentralGoogle Scholar
- Chiang AC, Massagué J. Molecular basis of metastasis. N Engl J Med. 2008;359:2814–23.View ArticlePubMedPubMed CentralGoogle Scholar